



TOMÁS J. ARAGÓN, M.D., Dr.P.H.
Director and State Public Health Officer

State of California—Health and Human Services Agency
California Department of Public Health




GAVIN NEWSOM
Governor

September 01, 2023

IZB-FY-23-24-03

TO: California Vaccines for Children (VFC) Providers

FROM: Robert Schechter, M.D., Chief 
Center for Infectious Diseases
Division of Communicable Disease Control, Immunization Branch

SUBJECT: **Addition to the VFC formulary: new one-vial presentation of Menveo**

Dear VFC Provider,

The US Food and Drug Administration (FDA) has licensed a new presentation of Menveo (GlaxoSmithKline, or GSK), a formulation of meningococcal conjugate vaccine, (MenACWY).

The new one-vial presentation of Menveo is licensed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135 in individuals 10 through 55 years of age. For comparison, the continuing two-vial formulation of Menveo is licensed for individuals 2 months through 55 years of age.

Per [VFC resolution](#) 6/20-1, both [Menveo one-vial and two-vial presentations](#) will be available through the VFC program. MenACWY vaccines are available to any VFC-eligible child:

- 2 months through 10 years at [increased risk](#) for meningococcal disease attributable to serotypes A, C, W, and Y.
- All children aged 11 through 18 years.

Although Menveo two-vial presentation is indicated in children 2 months -18 years, providers are encouraged to limit use of the existing Menveo two-vial presentation to children 2 months to 2 years, as this is the only MenACWY formulation available to this age group.

Storage and handling: Detailed information can be found in the [Menveo FDA package insert](#).



Menveo one-vial presentation is supplied in a box containing

- 10 vials containing Menveo (pink cap)
- Menveo one-vial presentation does NOT require reconstitution prior to administration.
- Storage
 - Keep refrigerated at 36° to 46°F (2° to 8°C). Protect vials from light.
 - **DO NOT FREEZE**

Menveo two-vial presentation is supplied in a box containing

- 5 vials of liquid MenCWY-135 antigen (vial 1, gray cap)
- 5 vials of lyophilized MenA antigen (vial 2, orange cap)
- Storage prior to reconstitution
 - Keep refrigerated at 36° to 46°F (2° to 8°C). Protect vials from light.
 - **DO NOT FREEZE**
- Storage after reconstitution
 - If not used immediately, store reconstituted vaccine between 36° to 77°F (2° to 25°C) and administer within 8 hours. Discard if frozen or not used within 8 hours.

The vial containing MenCYW-135 liquid conjugate (gray cap) is used to reconstitute the vial containing MenA lyophilized conjugate component (orange cap) to form Menveo.

Dosage and Administration: A single dose of either presentation of Menveo is 0.5 mL. Administration is via the intramuscular route according to [currently recommended ACIP immunization schedules](#) for age and indication.

VFC ORDERING

Providers may order Menveo and other existing MenACWY products through their [MyVFCvaccines](#) account.

If you are currently using the Menveo two-vial product, there is no need to submit a "[Provider Request Form to Update Vaccine Brand Products Administered](#)" to the VFC Program. However, if your practice plans on switching to Menveo from another vaccine product, submit the form and keep the following information in mind:

- Careful consideration should be given when selecting alternative brands or products in order to minimize the impact on provider practices.
- Implementation of a different vaccine brand or product should be approved by your practice's medical director or Provider of Record.
- Staff should be thoroughly informed and educated on changes to vaccines and its impact on vaccine ordering, storage, administration, and documentation.
- As your practice transitions to a new product, managing on-hand inventory appropriately is a key factor in preventing unnecessary vaccine wastage. Your initial request for a new vaccine product may be reduced to help minimize vaccine waste as you transition from the product currently being used by your practice.
- A plan to deplete excess inventory must be in place prior to transitioning to a new product. It is the provider's responsibility to ensure all VFC-supplied vaccines are used prior to their expiration date or transferred to another VFC Provider who can use them. Viable unused doses of these individual vaccines cannot be returned to the VFC Program.

BILLING FOR VFC VACCINE

CHDP:

Claims may be submitted for VFC-supplied doses of Menveo administered to CHDP-eligible patients through age 18 years. Please refer to the CHDP Provider manual and relevant [CHDP Provider Information Notice](#).

CHDP providers with additional questions are advised to contact their [County CHDP Program](#).

Medi-Cal Fee-For-Service (FFS):

To bill Medi-Cal FFS for administration of VFC-supplied doses of Menveo, use the appropriate CPT-4 code for **Menveo (90734)**, followed by the "-SL" modifier, in total **90734-SL**. Providers will only be reimbursed for the administration fee when using VFC vaccines for Medi-Cal FFS-eligible patients.

For specific information and details on Medi-Cal billing, please refer to the [Medi-Cal provider manual on VFC](#). Providers with questions on Medi-Cal billing policies and procedures and Provider manual information may call the Telephone Service Center (TSC) at 1-800-541-5555.

Medi-Cal Managed Care

Please contact the specific Medi-Cal managed care health plan for information on immunization billing and reimbursement.

Other codes for the use of Menveo not supplied by VFC:

- The CPT-4 code for **Menveo** is **90734**
- The ICD-10-CM code for an encounter for immunization is **Z23**.

Resources

- [ACIP Child and Adolescent Immunization Schedule](#)
- [Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020 | MMWR \(cdc.gov\)](#)
- [Menveo FDA Package Insert](#)
- [Menveo presentations CDC job aid](#)
- [VFA/VFC Vaccine Eligibility Guidelines Table](#)
- [VFC resolutions](#)